Sanofi Aventis Us Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SANOFI AVENTIS US, and when can generic versions of SANOFI AVENTIS US drugs launch?
SANOFI AVENTIS US has one hundred and twenty-two approved drugs.
There are ten US patents protecting SANOFI AVENTIS US drugs.
There are two hundred and seventeen patent family members on SANOFI AVENTIS US drugs in fifty-two countries and one hundred and fifteen supplementary protection certificates in nineteen countries.
Summary for Sanofi Aventis Us
International Patents: | 217 |
US Patents: | 10 |
Tradenames: | 97 |
Ingredients: | 85 |
NDAs: | 122 |
Drugs and US Patents for Sanofi Aventis Us
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | AMARYL | glimepiride | TABLET;ORAL | 020496-001 | Nov 30, 1995 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | BRICANYL | terbutaline sulfate | TABLET;ORAL | 017618-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Sanofi Aventis Us | LOVENOX | enoxaparin sodium | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 020164-009 | Jan 23, 2003 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | HYDROXYSTILBAMIDINE ISETHIONATE | hydroxystilbamidine isethionate | INJECTABLE;INJECTION | 009166-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sanofi Aventis Us
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | LOVENOX (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 020164-005 | Mar 27, 1998 | RE38743 | ⤷ Try a Trial |
Sanofi Aventis Us | INTAL | cromolyn sodium | CAPSULE;INHALATION | 016990-001 | Approved Prior to Jan 1, 1982 | 3,860,618 | ⤷ Try a Trial |
Sanofi Aventis Us | LOVENOX (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 020164-001 | Mar 29, 1993 | 4,692,435 | ⤷ Try a Trial |
Sanofi Aventis Us | CEPHULAC | lactulose | SOLUTION;ORAL, RECTAL | 017657-001 | Approved Prior to Jan 1, 1982 | 3,461,204 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SANOFI AVENTIS US drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 7 mg and 14 mg | ➤ Subscribe | 2016-09-12 |
➤ Subscribe | Tablets | 300 mg/25 mg | ➤ Subscribe | 2006-06-06 |
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2013-07-01 |
➤ Subscribe | Injection | 5 mg/mL, 10 mL and 20 mL vials | ➤ Subscribe | 2007-02-09 |
➤ Subscribe | Injection | 200 mg/40 mL | ➤ Subscribe | 2007-07-16 |
➤ Subscribe | Injection | 100 mg/mL, 3 mL vials | ➤ Subscribe | 2006-12-07 |
➤ Subscribe | Extended-release Tablets | 12.5 mg | ➤ Subscribe | 2006-01-19 |
➤ Subscribe | Tablets | 150 mg/12.5 mg and 300 mg/12.5 mg | ➤ Subscribe | 2004-11-10 |
➤ Subscribe | Tablets | 75 mg, 150 mg and 300 mg | ➤ Subscribe | 2004-05-25 |
➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-03-04 |
➤ Subscribe | Injection | 40 mg/mL, 0.5 mL and 2 mL vials | ➤ Subscribe | 2009-06-30 |
➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2007-02-09 |
➤ Subscribe | Injection | 5 mg/mL, 40 mL vial | ➤ Subscribe | 2011-03-23 |
➤ Subscribe | Extended-release Tablets | 6.25 mg | ➤ Subscribe | 2006-02-24 |
International Patents for Sanofi Aventis Us Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Guatemala | 201200075 | ⤷ Try a Trial |
Malaysia | 155613 | ⤷ Try a Trial |
Tunisia | 2012000188 | ⤷ Try a Trial |
Brazil | 112012006184 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sanofi Aventis Us Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3300601 | CA 2022 00030 | Denmark | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AF DAUNORUBICIN OG CYTARABIN; REG. NO/DATE: EU/1/18/1308 20180827 |
1667986 | 2013C/036 | Belgium | ⤷ Try a Trial | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION |
0454511 | C980039 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: IRBESARTAN, DESGEWENST IN DE VORM VAN EEN ZOUT EN/OF EEN HYDRAA T; REGISTRATION NO/DATE: EU/1/97/046/001 - 009 19970827 |
2344130 | 132017000093887 | Italy | ⤷ Try a Trial | PRODUCT NAME: OZENOXACIN(DUBINE); AUTHORISATION NUMBER(S) AND DATE(S): ES/H/414/01/DC, 20170519;045237017, 20170711 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.